Exciting news from our portfolio company, phenomixsciences, as they announce the launch of their innovative My Phenome Hungry Gut test.

The test marks a transformative shift to personalized #obesity treatment

Read more about the launch FierceBiotech: hubs.li/Q01LbS9p0

Obesity medicine stands to benefit from a 2000 SNP #blood test that matches four primary #obesity phenotypes to optimal treatment strategies, says Mark Bagnall, CEO of phenomixsciences. Mayo Clinic
genengnews.com/topics/transla…

Congratulations to our founder, Andres Acosta who has received the prestigious New Investigator Award from Mayo Clinic Department of Medicine.

First step to treating obesity and associated co-morbidities is to recognize #obesity as a disease.

Congratulations to Andres Acosta, who was named as the recipient of the 2021 Mayo Clinic Department of Medicine New Investigator Award.

Thanks JENNIFER NG, MD for calling awareness to the importance of #obesityphenotyping to improve #weightloss treatment.
Read the full article and follow Obesity Medicine Association to learn more.
#obesityawareness #endobesity

ow.ly/6e6950FHr33

Excited to have phenomixsciences's founder Andres Acosta share his expertise at National Academies #FoodForum on August 10-12 about precision medicine in nutrition.

Where do you think MN ranks in the US for medtech innovation? medicaldesignandoutsourcing.com/the-top-10-med…
Number 2! Thanks to the strong community organizations like Medical Alley and UniversityEnterpriseLabs and so many more who have invested in making MN a #medtech hub for #innovationinhealthcare .

Our Silicon Valley #innovation subsidiary, Health2047, remains committed to driving #healthcare modernization. Learn how phenomixsciences, @GroupEmergence, & SiteBridge Research joined the existing stable of bold spinouts: spr.ly/6016yHyhr

#health2047

#health2047

Check out our website to learn more about how Phenomix has defined four different obesity phenotypes and targeted interventions!

Click on the 'How It Works' tab and download the 'Healthcare Provider Overview' to learn more!

What makes Health2047 companies special?

Health2047 companies:
✨Work to break the curve, not just bend it!
✨Have a differentiated solution!
✨Have an outstanding team!

✨Phenomix Sciences is proud to be a Health2047 company.

The FDA has approved a new version of Wegovy, a popular diabetes medicine, as a weight-loss drug. Studies found participants taking the drug had an average weight loss of 15%, about 34 pounds.
trib.al/etAJf15

Is sugar killing us?

@AmericanHeartAssociation reports that adults eat 60lbs of sugar/year and kids are consuming 65lbs of sugar/year.

We fill a bathtub full of sugar every year with the beverages we drink. Wow!
heart.org/en/healthy-liv….

Great job Anas Hashem, MD! Discussing about cholesterol absorption and obesity Digestive Disease Week Mayo Clinic Gastroenterology & Hepatology American Gastroenterological Association (AGA)

'We're committed to advancing more cures, connecting more patients to our expanded expertise and transforming health care for people everywhere,' says Dr. Gianrico Farrugia, Mayo Clinic's president and chief executive. startribune.com/mayo-s-new-res…

Colorectal cancer is a leading cancer among men and women around the world. Many colorectal cancers are likely to spread to other organs, with the most common site of metastases being the liver.

Dr. Sean Cleary, Mayo Clinic in the U.S., explains: bit.ly/3bFsSJx

Current strategies for treating #obesity rely on a 'one-size-fits-all' approach. Phenomix Sciences founder, Andres Acosta is moving the field forward through his research and leadership of the Precision Medicine Obesity Lab at Mayo Clinic. Learn more: mayo.edu/research/labs/…

What does your blood tell you about your ability to lose weight? Obesity phenotyping is a step toward understanding your individual weight loss journey.
Article write up in HIT Consultant Media by Fred Pennic.
#obesity #phenotyping #Metabolomics
May 4, 2021
hitconsultant.net/2021/05/04/phe…